Try our Advanced Search for more refined results

Barr Fires Back At Celgene In Thalomid Patent Case

By Pete Brush (September 5, 2008, 12:00 AM EDT) -- In the latest salvo over generic versions of the cancer drug Thalomid, generic-drug maker Barr Laboratories Inc. said on Thursday that Celgene Corp.'s patent claims are unenforceable because the inventor withheld material information as the application wended its way through the U.S. Patent and Trademark Office....

Law360 is on it, so you are, too.

A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.


A Law360 subscription includes features such as

  • Daily newsletters
  • Expert analysis
  • Mobile app
  • Advanced search
  • Judge information
  • Real-time alerts
  • 450K+ searchable archived articles

And more!

Experience Law360 today with a free 7-day trial.

Start Free Trial

Already a subscriber? Click here to login

Related Sections

Law Firms

Companies

Government Agencies

Patents

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!